Wegovy 1.7 mg: the penultimate step before full maintenance

The most common misconception: 1.7 mg isn't a low dose that's 'not working'

Plenty of people reach the 1.7 mg Wegovy dose and feel quietly disappointed. They've heard about 15–20% weight loss in clinical trials, and a few months in they're not there yet. The assumption is that the dose isn't strong enough, but that reading misses how the titration schedule works.

Wegovy's dose escalation exists almost entirely to protect your digestive system. Semaglutide slows gastric emptying and changes the way appetite signals reach your brain; introduced too quickly, that causes significant nausea, vomiting and other gastrointestinal upset. The lower doses (including 1.7 mg) are calibrated for tolerance, not for maximum effect. The licensed maintenance dose, where the bulk of the published weight-loss results were measured, is 2.4 mg. You have to get there first.

This matters because people sometimes ask their prescriber to stay at 1.7 mg indefinitely, or worry that stepping up will make side effects worse. In practice, the 1.7 mg to 2.4 mg transition is the last step, and for many people it's the smoothest, because the body has already had three months of adjustment. Our clinical team at nume sees this question regularly, the answer is usually the same: 1.7 mg is a bridge, not a destination.

The NHS patient information for semaglutide sets out the full dosing pathway in plain language if you want the official picture alongside what a prescriber tells you.

What actually changes at 1.7 mg compared to 1 mg

Moving from 1 mg to 1.7 mg Wegovy is a meaningful step up, roughly 70% more semaglutide per weekly dose. Most people notice increased appetite suppression within the first week or two after switching. Meals feel satisfying on smaller portions. The urge to snack between meals often drops further. Some find their energy feels slightly lower in the first few days; that typically settles.

Side effects at 1.7 mg follow the same GI-led pattern seen throughout the schedule: nausea, looser stools, indigestion, or a feeling of fullness that arrives quickly at the table. They tend to be most noticeable in the week or two after a dose increase, then ease as the body adjusts. If you experienced significant diarrhoea at an earlier stage (something our page on gastrointestinal symptoms at 1 mg covers in more detail) it's worth flagging this to your prescriber before moving up, rather than just pushing through.

One detail worth knowing: if you miss a dose by more than five days, the standard clinical guidance is to skip that injection rather than take it late, then continue your normal schedule the following week. The specific advice for your situation always sits with your prescriber and the Patient Information Leaflet, not a general article.

The decision to move from 1.7 mg to 2.4 mg is explored in more depth on our 1.7 mg to 2.4 mg transition page if you're weighing up what that step involves.

Who reaches 1.7 mg Wegovy UK, and when

Under the licensed titration schedule, 1.7 mg is the expected dose for weeks 13–16 of treatment, assuming tolerability at each preceding level. Starting at 0.25 mg and moving up roughly every four weeks, most people get their 1.7 mg pen around the four-month mark. That timeline can extend if a prescriber advises staying longer at an earlier dose, which is clinically appropriate for some patients, not a failure.

Eligibility for Wegovy in the UK requires a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone doesn't determine suitability; a full clinical picture is what a prescriber uses.

Privately, through a regulated online pharmacy like nume's Wegovy service, there's no GP referral or waiting list involved. You complete a consultation, it's reviewed the same day by a GPhC-registered prescriber, and treatment is dispatched once approved. Dose progression is clinically re-reviewed with every repeat order. For context on what private Wegovy treatment costs across a full titration schedule, our Wegovy prices page lays it out plainly.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance TA875, with specific eligibility criteria and typically significant waiting times. The private route exists for people who don't meet NHS thresholds or prefer not to wait.

The pen format for 1.7 mg, and what to expect when it arrives

Wegovy is supplied as a pre-filled injection pen; each pen delivers four weekly doses at the prescribed strength. At 1.7 mg, each weekly injection is self-administered as a subcutaneous injection into the abdomen, thigh or upper arm, rotating the site each week. The pen requires refrigeration between 2°C and 8°C, most people keep it in the fridge door, though not in the freezer compartment or pressed against the back wall where it could freeze. The exact storage and handling instructions are in your Patient Information Leaflet and should always be your primary reference.

If you want a closer look at how the physical pen at this strength works before your first injection, our guide to the 1.7 mg Wegovy pen covers the practicalities. And if you're building a picture of the full Wegovy dose range before your consultation, the overview of all Wegovy doses is a good place to start.

When you're ready to talk to a prescriber about starting or continuing Wegovy, starting a free consultation with nume takes a few minutes, your answers are reviewed the same day by a real clinician, and if approved, your pen is dispatched for free next-working-day delivery.